Stockreport

DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF dosed in the DESTINY-Lung06 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) plus pembrolizumab versus pembrolizumab, platinum-based chemotherapy and pemetrex [Read more]